Trials / Unknown
UnknownNCT05273047
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
Assessment and Follow-up of Patients With KRAS G12C-mutated Metastatic Non-Small Cell Lung Cancer Who Received Sotorasib as Part of the French Early Access Program (ATU)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 458 (actual)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the demographic and molecular characteristics of patients.
Detailed description
The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the demographic and molecular characteristics of patients. The objective of this retrospective observational, multicenter, cohort study is to describe, in real life, the characteristics and evolution of NSCLC patients with a KRAS G12C mutation, treated with sotorasib in the framework of the cohort ATU in France.
Conditions
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2023-08-30
- Completion
- 2024-12-31
- First posted
- 2022-03-10
- Last updated
- 2023-09-29
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05273047. Inclusion in this directory is not an endorsement.